Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Cancer. 2021 Aug 3;127(21):3957–3966. doi: 10.1002/cncr.33679

Table 4:

What type of genetic testing should be performed?*

Consensus question Single-gene Multigene

In general, should individuals with suspicion for a classic syndrome be considered for single gene or multigene panel testing? 83% 17%

In general, should individuals without suspicion of a classic syndrome but at least one risk factor for hereditary kidney cancer be considered for single gene or multigene panel testing? 10% 90%

Yes No

An individual with kidney cancer undergoes somatic tumor profiling and is found with an alteration in a cancer gene associated with hereditary RCC (not VHL), in the absence of risk factors, should this individual undergo genetic risk assessment?* 21% 79%**

If the above individual were to pursue genetic risk assessment for an alteration identified on a somatic panel, should testing consist of a single-gene assay? 97% 3%

Should a negative somatic tumor profiling report (without germline testing) influence the decision to pursue genetic risk assessment? 39% 61%
*

Statements in bold represent those with reached consensus

**

79% voted that the response to this question depends on the specific gene in question.